Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

U.S. Department of Health and Human Services
Rebecca Brown
 

 Contact Info

 
Tel: 301-594-0609
Email: brownrebecca@mail.nih.gov
 

 Select Experience

 
  • Assistant Clinical InvestigatorNIDDK, NIH2012–2015
  • Senior FellowNIDDK, NIH2008–2012
  • FellowNICHD, NIH2005–2008
  • ResidentRainbow Babies and Children’s Hospital2002–2005
  • Lasker Tenure Track InvestigatorNIDDK, NIH2015-present
  • M.H.Sc.Duke University2011
  • M.D.Mayo Medical School2002
 

 Related Links

 

Rebecca J. Brown, M.D., M.H.Sc., Lasker Tenure Track Investigator

Lasker Tenure Track Investigator, Section on Translational Diabetes and Metabolic SyndromesDiabetes, Endocrinology, and Obesity Branch
Specialties
  • Clinical Research
Research Summary/In Plain Language

Research Summary

Research Goal

Our goal is to understand the basic mechanisms regulating energy metabolism in humans. We use rare diseases as models to understand perturbations in pathways regulating energy metabolism and apply what we learn from rare diseases to common conditions such as obesity and the metabolic syndrome.

Current Research

Our group studies pathophysiology and clinical therapeutics for rare disorders of extreme insulin resistance including lipodystrophy, mutations of the insulin receptor, and autoimmune conditions affecting insulin signaling. We are particularly interested in understanding the mechanisms of action of the adipokine, leptin, in improving metabolic disease in lipodystrophy.

Applying our Research

We conduct clinical trials to study new treatments for rare diseases, thereby improving the health of individuals with these rare conditions. In addition, we hope to apply what we learn from treating rare diseases to improve health in people with common conditions.

Need for Further Study

Further study is needed to understand the mechanism of action of leptin in treatment of lipodystrophy and other disorders of extreme insulin resistance.